Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
BMB.J. MonkMPMaria Pilar Barretina-GinestaBPBhavana PothuriIVIgnace VergoteWAWhitney A. Spannuth Graybill
Florida Cancer Specialists & Research Institute · Institut d'Investigació Biomèdica de Girona · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
144
total citations
- FWCI
- 36.17
- Percentile
- 100%
- References
- 38
Citations per year
Authors
30- BMB.J. MonkCorresponding
Florida Cancer Specialists & Research Institute
- MPMaria Pilar Barretina-Ginesta
Institut d'Investigació Biomèdica de Girona
- BPBhavana Pothuri
Gynecologic Oncology Group
- IVIgnace Vergote
The European Academy of Gynaecological Surgery, KU Leuven
- WAWhitney A. Spannuth Graybill
Medical University of South Carolina
Topics & keywords
Topics
Keywords
- Medicine
- Hazard ratio
- Internal medicine
- Population
- Oncology
- Confidence interval
- Progression-free survival
- Ovarian cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- PPfizer
- AAstraZeneca
- CCelgene
- KTKaryopharm Therapeutics
- RPRegeneron Pharmaceuticals
- NNovocure
- COClovis Oncology
- MTMersana Therapeutics
- MGMyriad Genetics
- IIncyte
- NONRG Oncology
- PBPuma Biotechnology
- MMacroGenics
- SSeagen
- DDaiichi-Sankyo
- EEisai
- TIToray Industries
- PPharmaMar
- GGenentech
- ESEMD Serono
- LOLoxo Oncology